Related Experiment Video
Updated: Jul 11, 2026

Determination of the Relative Potency of an Anti-TNF Monoclonal Antibody (mAb) by Neutralizing TNF Using an In Vitro Bioanalytical Method
Published on: September 16, 2017
[Biological therapy with anti-TNF antibodies. Extending the spectrum of its indications?]
M López Rodríguez1, M García Arias, J Gómez Cerezo
1Servicio de Medicina Interna. Hospital Universitario La Paz. Madrid. España. monlr2001@hotmail.com
Tumor necrosis factor (TNFalpha) is a main mediator in the inflammatory answer of many diseases. The anti-TNFalpha antibodies (infliximab, etanercept, adalimumab) block their action, preventing the inflammatory answer and the damage it produces. In this paper, we review the treatment of some diseases in which these drugs are experimentally used. These are: ulcerative colitis, sarcoidosis, graft-versus-host disease, adult Still's disease, some systemic vasculitis, systemic lupus erythematosus and Behçet disease.
Tumor necrosis factor (TNFalpha) is a main mediator in the inflammatory answer of many diseases. The anti-TNFalpha antibodies (infliximab, etanercept, adalimumab) block their action, preventing the inflammatory answer and the damage it produces. In this paper, we review the treatment of some diseases in which these drugs are experimentally used. These are: ulcerative colitis, sarcoidosis, graft-versus-host disease, adult Still's disease, some systemic vasculitis, systemic lupus erythematosus and Behçet disease.
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Immunotherapy
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

